Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
So it's 16mil out 27.1 total. Thanks.
"Management believes that the amounts available from Aspire (currently 16 million) and under the Company's effective shelf registration statement will be sufficient to fund the Company's operations for the next 12 months.
Ongoing pipeline developments should improve funding.
Frrol your exactly right that main data was released Nov9. Missling also gave us an excellent insight on upcoming PartB on Nov.9. Preliminary interim readout of PART B data, ANAVEX 2-73 improved ADCS-ADL score, a functional measurement, over a period of 12 weeks by +3.21 over baseline, with 11 out of 14 (78.6%) patients improving. Both MMSE and ADCS-ADL are regulatory approved endpoints for pivotal Alzheimer’s disease trials. It will be interesting to see whether the 3 patients also improved with increased time.
So no Celgene??
Thirty minute time slot could leave room for a good Q&A. Live feed from conference could be a real eye opener.
Forbes article: When is a competing drug’s failure not a good thing? When your drug has the same mechanism of action.
Sciences (AXON) dropped 25% in early Tuesday trading on news that Pfizer PFE -3.45% (PFE) has discontinued phase 2 testing of PF-05212377, a 5-HT6 receptor antagonist being developed for Alzheimer’s Disease.
I would say this puts Anavex in the drivers seat.
Here to ride a rocket not a bull thank you. This stock in this sector is rocket material.
Yes and this from November 19 2015 PR: “ANAVEX 2-73 demonstrated convincing data in three well-established and predictive preclinical anti-seizure models with potentially more favorable side effect profile than currently marketed epilepsy drugs,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. “The cognitive-enhancing features of ANAVEX 2-73 might be a differentiating factor since seizures cause neuro-cognitive impairments, which can be worsened by current epilepsy medications. With recent data from the Phase 2a trial for ANAVEX 2-73, the Company is encouraged to continue exploring this additional indication.”
Yes "undisclosed indication" could be revealed at the February 2016 Epilepsy Conference. Very good news coming.imo
"The trial was expected to enroll 100 subjects and actually enrolled 115 subjects". I take this as a vote of confidence.
Thanks for the update BooDog. Scheduling has it for Tuesday, Feb 9, 1:30 PM - 2:00 PM – Conrad
Ditto.eom
I agree it could make a world of difference if brilacidin MoA was publicized. The world is on fire for new antibiotics as we wait in never land.
I think your referring to VISA being granted an IPO and bought into by some of our illustrious elected banking overseers.
Hillary Clinton said she would put a cap on drug prices. Price capping anything sounds good for getting votes but in reality it only makes for scarcity then rationing.
And yes go Panthers.
There is only one suit not multiple suits...the law firms putting out the notices are just advertising to get a piece of the action that seems weak on merit.. Happens to companys everyday..and sadly has become the american way to put out a law suit ahead of a plaintiff. The science is strong here.
Everybody should be adding at these prices. I bought at .90 cents three years ago when ctix had a lot less going for it.
"Our team is encouraged by these findings and we look forward to advancing ANAVEX 2-73 into a larger Phase 2/3 study for Alzheimer’s as well as initiating a double-blinded, randomized, placebo-controlled Phase 2 trial for ANAVEX 2-73 in an additional indication associated with cognitive impairment."
Agree this is Extremely encouraging!!
Thanks for the response. Sounds encouraging, hopefully its true.
You mentioned "highly effective in some humans". Never heard it put that way. You have some first hand knowledge??
That is the order of things. Retail buys on hope and sells on fear. Next clinical update any day now.
I'm holding and here's why: NEW YORK, NY, November 18, 2015 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, announces that it is moving forward with the development program for ANAVEX 2-73. Guidance received from the FDA confirms the Company’s strategy to advance ANAVEX 2-73 for the treatment of Alzheimer’s disease in a larger double-blinded, randomized, placebo-controlled Phase 2/3 trial.
Yes hard to watch. I'm long since May so holding for phase 3 and boom to the moon. Good luck.
Wording in the 10k suggests there is more to subpoena then meets the eye. The sec investigation may help all our investments in the long run. Hoping for a quick resolve.
The other company was taken down by a tangible hit piece from shorts that the CEO was able to reponded to directly and dispute. There is no hit piece here for Missling to respond too but a sec subpoena that is for all we know out of Misslings hands. Time will tell.
You say it's the same thing..And what hit piece does Missling respond too? There is none. A response from Missling would be great but we don't know the story behind the subpoena. 12 week data is what I'm waiting on at this point.
Thanks for that good info. If I read Boodogs post right it appears anavex was once on the list to present.
Received the following from IR:
Dear xxxxx,
At this time Anavex is not listed as a presenting company at the BioTech Showcase 2016.
Information regarding upcoming conferences will be issued as developments warrant via the company’s events page.
Please do not hesitate to contact our office if we can be of further assistance.
On behalf of Anavex Life Sciences Corp.,
Investor Relations
Toll Free (North America): 1 (866) 505-2895
Outside North America: +1 (416) 489 0092
Fax: +1 (416) 352 5239
ir@anavex.com
The negative law firm investor alerts are stacking up. Got to weed through them to find his last positive PR. Dr Missling has to make a statement and soon.
That other stock is a pinkie that has struggled from CEO not following through causing an opening for a huge short to step in. I own both with no complaints.
Received this from IR a little while back. She says they are scheduled to present, have not seen Anavex on the preliminary list yet.
Dear xxxxx,
Thank you for your email and interest in Anavex Life Sciences Corp. (Nasdaq: AVXL).
Anavex is scheduled to present at the BioTech Showcase 2016. This is an annual conference at which the company has previously presented.
For your interest, the 2015 press release is available here: www.anavex.com/?news=anavex-to-present-at-biotech-showcase-2015-in-san-francisco. The 2016 presentation is also scheduled to be a corporate overview.
Please do not hesitate to contact our office if we can be of further assistance.
On behalf of Anavex Life Sciences Corp.,
Investor Relations
Toll Free (North America): 1 (866) 505-2895
Outside North America: +1 (416) 489 0092
Fax: +1 (416) 352 5239
ir@anavex.com
Thanks for your input here Karin I know you have seen this type of unscrupulous law suit fishing in another bio. I have not heard or seen of an actual suit with this one. Fishing all triggered by SEC report.
Adding on the dips..Unlike that other one starts with an A..were likely to see big upswing here on cognitive data very soon. Phase 2/3 already in the works. Plus one more phase2 trial in the mix, most likely Parkinsons Disease or on the outside Epilepsy but we shall all see.
CC
Biotech by design is long and downright frustrating to shareholders at times. So many variables in human testing and procedure that it seems endless. Phase3 will be announced but not until after the variables have been met. A large double B phase3 test is an enormous undertaking for a small biotech but we will get there.
"big buyers once it's off the pinks...not holding my breath that's for sure. So far time has not worked, going to take some real dynamite news.
Phase 2a Dose Finding, PK/PD and 12 Month Exploratory Efficacy Study of ANAVEX2-73 in Patients With Alzheimer's Disease.
Estimated Study Completion Date: December 2015.
I look for further data in January...possibly at Biotech Showcase 2016 - San Francisco. January 11–13. Nothing written in stone from Missling yet.
Listen good. There is no lawsuit only boiler plate attorney notices.
Yes Thanks. Longs need to focus on the substance of today's PR. The substance been lost in the SEC investigation that clearly has nothing to do with AVXL trials going forward imo.
Missling stated "the Company believes the subpoena and investigation relate to the recent unusual activity in the market for the Company's shares."
Upcoming Milestones:
PART B data updates for 12, 26, 38, 52 week timeframes of the ongoing Phase 2a Alzheimer’s trial for ANAVEX 2-73.
Report pharmacokinetics and pharmacodynamics (PK/PD) data for PART A of the Phase 2a trial.
Initiate double-blinded, randomized, placebo-controlled Phase 2 human trial of ANAVEX 2-73 in non-disclosed indication.
In addition to ongoing Phase 2a trial currently in PART B, start larger, double-blinded, randomized, placebo-controlled Phase 2/3 trial of ANAVEX 2-73 for Alzheimer’s disease.
Advance preclinical research with ANAVEX pipeline compounds in neurodegenerative diseases, pain and various types of cancer – ongoing.
In-licensing to complement current pipeline – ongoing.
(Bold)New epilepsy study??